Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 4

1(20.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(2)

Phase 4(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05798156Phase 2Active Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Role: collaborator

NCT05551299Phase 4Recruiting

Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

Role: collaborator

NCT02599480Phase 2Completed

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

Role: collaborator

NCT05373498Recruiting

Resuscitation Registry in CHD

Role: collaborator

NCT04076527Unknown

Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis

Role: collaborator

NCT02924285Phase 3Completed

Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease

Role: collaborator

NCT04009434Not ApplicableUnknown

Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.

Role: collaborator

All 7 trials loaded